Quit rates were low in all three arms of the study: 7.3% (eCIG), 4.1% (placebo eCIG), and 5.8% (nicotine patch). Because the quit rates were substantially lower than anticipated in the power calculation of the study, it was not possible to discern whether there was a statistically significant difference between the quit rates on “real” vs placebo eCIGs. In any case, the difference between them would hardly appear to be clinically relevant. There were no differences shown in serious adverse events, but considering the fact that eCIG use may potentially span many years, it would be premature to conclude that long-term use of eCIGs is safe.
The trusted source for
healthcare information and